Pfizer, an American multinational pharmaceutical corporation, agreed to acquire Amplyx Pharmaceuticals, a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases. Financial terms were not disclosed. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies. We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections; with this acquisition, we look forward to progressing the development of a novel anti-fungal as well,” Angela Lukin, Pfizer Hospital Global President.